Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
cHMGCS CRISPR/Cas9 KO Plasmid (h): sc-417181
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- cHMGCS CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the cHMGCS genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: cHMGCS Antibody (A-6): sc-166763
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
cHMGCS CRISPR/Cas9 KO Plasmid (h) | sc-417181 | 20 µg | $397.00 |
Overview
HMGCS1 encodes cytosolic 3-hydroxy-3-methylglutaryl-CoA synthase (cHMGCS), a key enzyme of the mevalonate pathway that catalyzes formation of HMG-CoA from acetoacetyl-CoA and acetyl-CoA. This step supports sterol and isoprenoid biosynthesis, linking cellular acetyl-CoA availability to cholesterol production and prenylation-dependent signaling. HMGCS1 activity is tightly integrated with lipid homeostasis programs and feedback regulation of metabolic gene expression, influencing membrane biogenesis and redox balance. Dysregulation of mevalonate pathway flux has been associated with altered proliferation, metabolic stress responses, and phenotypes relevant to cardiovascular and neurodegenerative disease research.
cHMGCS CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the HMGCS1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the HMGCS1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the HMGCS1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish cHMGCS protein expression.
This CRISPR knockout system enables efficient generation of HMGCS1-deficient cell models for investigation of cHMGCS signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting HMGCS1 exon(s) critical for cHMGCS function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple HMGCS1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by cHMGCS CRISPR/Cas9 KO Plasmid (h) and cHMGCS CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the HMGCS1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by cHMGCS HDR Plasmid (h) and cHMGCS HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by HMGCS1 homology arms to support homology-directed repair at defined HMGCS1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.